Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 101 of 5804
-
New drug shows promise in rare nerve disease trial
Disease control CompletedThe primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Targeted drug shows promise for Gene-Driven lung cancers
Disease control CompletedThis is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise in aggressive brain cancer trial
Disease control OngoingThe proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy …
Phase: PHASE2, PHASE3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Hope for rare heart disease: new drug aims to slow deadly protein clumps
Disease control OngoingThis study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for hard-to-treat HIV: long-acting shot and pill combo tested
Disease control OngoingThe primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen for 14 days (functional monotherapy) in people with human immunodeficiency virus type 1 (HIV-1) (PWH) with multi-drug resista…
Phase: PHASE2, PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New clotting factor shows promise in reducing bleeds for hemophilia a patients
Disease control CompletedPrimary Objective: \- To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episode…
Phase: PHASE3 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 18:07 UTC
-
Gene therapy offers new hope for sickle cell patients
Disease control CompletedThe purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the Sickle Cell disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the βAS3 globin g…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New CAR-T therapy aims to wipe out myeloma cells
Disease control OngoingThe purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a single pill replace the shot for gonorrhea?
Disease control CompletedThis trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azi…
Phase: PHASE3 • Sponsor: Global Antibiotics Research and Development Partnership • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo may keep lung cancer from returning after surgery
Disease control OngoingThe main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to beat tough childhood leukemia
Disease control Recruiting nowThis phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug targets rare lung cancer mutation
Disease control OngoingCLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and …
Phase: PHASE1, PHASE2 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug aims to clear hidden leukemia before transplant
Disease control OngoingThis is a multi-center, phase 2A exploratory study of feasibility and effectiveness of Inotuzumab Ozagomicin in adult patients with Acute Lymphoid Leukemia (ALL) with positive minimal residual disease before any hematopoietic stem cell transplantation. The study is divided in tw…
Phase: PHASE2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can an immune booster keep melanoma from returning after surgery?
Disease control OngoingThe purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy shows promise against tough uterine cancer
Disease control CompletedThe purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New daily injection could cut bleeding in Tough-to-Treat hemophilia
Disease control OngoingThis study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleed…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
A simple urine test could revolutionize bladder cancer detection
Diagnosis Recruiting nowThis is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
Sponsor: Convergent Genomics, Inc. • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Could early kangaroo care save more tiny newborns?
Disease control CompletedWe will conduct an individually randomised, controlled, superiority trial with two parallel groups; an intervention arm allocated to receive KMC and a control arm receiving 'standard' care. The primary aim is to examine the impact of KMC initiated before stabilisation on mortalit…
Phase: NA • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Blood test could revolutionize colon cancer screening
Diagnosis OngoingThe ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 …
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Promising combo aims to stall aggressive breast cancer
Disease control OngoingThis study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into ot…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC